| 2025年年报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 传染病类(元) | 359,082,591.91 | 366,313,736.80 | 166,266,900.00 |
| 毒品及药物滥用类(元) | 287,233,683.98 | 231,686,879.42 | 102,314,200.00 |
| 妇女健康类(元) | 86,180,222.39 | 76,388,849.84 | 35,977,700.00 |
| 新冠单检产品收入(元) | - | - | 25,800,200.00 |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(元) | - | - | 20,264,000.00 |
| 心肌类(元) | 18,821,157.20 | 13,850,321.83 | - |
| 新冠检测类(元) | 17,123,495.40 | 57,190,689.84 | - |
| 肿瘤类(元) | 23,476,848.57 | 32,670,488.34 | - |
| 其他类(元) | 107,531,280.75 | 84,266,809.83 | 44,470,100.00 |
| 营业成本(元) | |||
| 传染病类(元) | 199,520,202.05 | 168,873,814.46 | - |
| 毒品及药物滥用类(元) | 111,760,148.95 | 81,602,800.88 | - |
| 妇女健康类(元) | 56,959,280.59 | 49,266,230.28 | - |
| 新冠单检产品收入(元) | - | - | - |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(元) | - | - | - |
| 心肌类(元) | 6,068,846.98 | 3,803,499.52 | - |
| 新冠检测类(元) | 12,128,299.05 | 32,897,570.01 | - |
| 肿瘤类(元) | 9,276,943.15 | 10,659,999.13 | - |
| 其他类(元) | 44,792,463.31 | 34,442,415.31 | - |
| 毛利(元) | |||
| 传染病类(元) | 159,562,389.86 | 197,439,922.34 | - |
| 毒品及药物滥用类(元) | 175,473,535.03 | 150,084,078.54 | - |
| 妇女健康类(元) | 29,220,941.80 | 27,122,619.56 | - |
| 新冠单检产品收入(元) | - | - | - |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(元) | - | - | - |
| 心肌类(元) | 12,752,310.22 | 10,046,822.31 | - |
| 新冠检测类(元) | 4,995,196.35 | 24,293,119.83 | - |
| 肿瘤类(元) | 14,199,905.42 | 22,010,489.21 | - |
| 其他类(元) | 62,738,817.44 | 49,824,394.52 | - |
| 毛利率(%) | |||
| 传染病类(%) | 44.44 | 53.90 | - |
| 毒品及药物滥用类(%) | 61.09 | 64.78 | - |
| 妇女健康类(%) | 33.91 | 35.51 | - |
| 新冠单检产品收入(%) | - | - | - |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(%) | - | - | - |
| 心肌类(%) | 67.76 | 72.54 | - |
| 新冠检测类(%) | 29.17 | 42.48 | - |
| 肿瘤类(%) | 60.48 | 67.37 | - |
| 其他类(%) | 58.34 | 59.13 | - |
| 收入构成(%) | |||
| 传染病类(%) | 39.92 | 42.48 | 42.08 |
| 毒品及药物滥用类(%) | 31.93 | 26.87 | 25.90 |
| 妇女健康类(%) | 9.58 | 8.86 | 9.11 |
| 新冠单检产品收入(%) | - | - | 6.53 |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(%) | - | - | 5.13 |
| 心肌类(%) | 2.09 | 1.61 | - |
| 新冠检测类(%) | 1.90 | 6.63 | - |
| 肿瘤类(%) | 2.61 | 3.79 | - |
| 其他类(%) | 11.96 | 9.77 | 11.26 |
| 毛利构成(%) | |||
| 传染病类(%) | 34.77 | 41.06 | - |
| 毒品及药物滥用类(%) | 38.23 | 31.21 | - |
| 妇女健康类(%) | 6.37 | 5.64 | - |
| 新冠单检产品收入(%) | - | - | - |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(%) | - | - | - |
| 心肌类(%) | 2.78 | 2.09 | - |
| 新冠检测类(%) | 1.09 | 5.05 | - |
| 肿瘤类(%) | 3.09 | 4.58 | - |
| 其他类(%) | 13.67 | 10.36 | - |